FDA approves Emmaus' Endari to treat sickle cell disease

The US Food and Drug Administration (FDA) has granted approval for Emmaus Life Sciences' Endari (L-glutamine oral powder) to reduce the severe complications of rare, debilitating and lifelong hereditary blood disorder sickle cell disease (SCD) in adu …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news